期刊
CURRENT GENE THERAPY
卷 16, 期 1, 页码 56-64出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566523216666160104141644
关键词
HIV-1; Gene therapy; Humanized mice; CCR5; CD4(+) T cells; DNA; RAG
资金
- Agence Nationale de la Recherche contre le SIDA (ANRS)
- Fond Pierre Berge /SIDAction
- ANRS
Immunodeficient mice reconstituted with human CD4(+) T cells, which can be achieved either by transfer of mature cells or immature progenitors, represent the only animal model to study HIV-1 infection of human lymphocytes in vivo. However, the immunocompromised status of most of these models currently rule out their use for vaccine studies. Nevertheless, the model might be ideally suited for HIV-1 gene therapy studies since eliciting an efficient anti-viral immune response is not the primary end-point. Rather, HIV-1 gene therapy should protect CD4(+) T cells from HIV-1-induced deletion and/or reduced viral replication. Here, we describe recent advancements in the field of HIV-1 gene therapy, focusing on tools and targets validated in various models of humanized mice. From the analysis of this literature, it appears that strategies targeting viral entry, by means of neutralizing antibodies or fusion inhibitors, are the most promising so far. Indeed, strategies targeting viral entry have moved to the clinic with encouraging results. Thus, humanized mice should be considered as the prime model to devise the safer and most effective HIV-1 gene therapy strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据